Stock CDXS CODEXIS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Company Codexis, Inc.

Equities

CDXS

US1920051067

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-26 pm EDT 		5-day change 1st Jan Change
2.66 USD +0.38% Intraday chart for Codexis, Inc. -6.01% -12.79%
Apr. 11 Codexis, Inc. Appoints Carole Cobb to Its Strategic Advisory Board CI
Feb. 29 Benchmark Upgrades Codexis to Buy From Hold, Price Target is $9 MT

Business Summary

Codexis, Inc. is an enzyme engineering company. It is leveraging its CodeEvolver technology platform to discover, develop, enhance, and commercialize novel, high performance enzymes and other classes of proteins. It utilizes its CodeEvolver technology platform to develop optimized enzymes that are used by some pharmaceutical companies to reduce their costs and improve the efficiency and productivity of their manufacturing processes for small molecule therapeutics. It is developing its Enzyme-Catalyzed Oligonucleotide Synthesis (ECO Synthesis) manufacturing platform to enable the scaled manufacture of RNA interference (RNAi) therapeutics through an enzymatic route. It also uses the CodeEvolver platform technology to develop enzymes for the synthesis of nucleic acids, such as DNA/RNA, including enzymes utilized in its ECO Synthesis manufacturing platform, where its enzymes are poised to deliver many of the same benefits it offers in pharmaceutical manufacturing.

Number of employees: 174

Sales per Business

USD in Million2022Weight2023Weight Delta
Biocatalysts, Pharmaceutical Intermediates, and Codex Biocatalyst Panels and Kits
61.2 %
- - 43 61.2 % -
Research and Development
38.8 %
- - 27 38.8 % -

Sales per region

USD in Million2022Weight2023Weight Delta
China
28.9 %
-- 20 28.9 % -
United States
19.5 %
0 0.0 % 14 19.5 % -
APAC
18.8 %
65 46.9 % 13 18.8 % -79.70%
EMEA
16.1 %
57 40.8 % 11 16.1 % -80.00%
Switzerland
15.8 %
-- 11 15.8 % -
Ireland
0.7 %
-- 1 0.7 % -
Americas
0.0 %
17 12.3 % 0 0.0 % -99.81%

Managers

Managers TitleAgeSince
Stephen Dilly CEO
 Chief Executive Officer 64 20-06-15
Sriram Ryali DFI
 Director of Finance/CFO 43 23-01-22
Margaret Fitzgerald CMP
 Compliance Officer 53 22-10-31
Kevin Norrett COO
 Chief Operating Officer 51 22-10-02
Stefan Lutz CTO
 Chief Tech/Sci/R&D Officer - 20-05-04
Karen Frechou-Armijo HRO
 Human Resources Officer - 21-11-14
Robert Sato LAW
 General Counsel - 06-12-31
Laurie Heilmann SAM
 Sales & Marketing 68 19-02-24

Members of the board

Members of the board TitleAgeSince
David Smith BRD
 Director/Board Member 64 16-02-29
Rahul Singhvi BRD
 Director/Board Member 59 22-09-27
Stephen Dilly CEO
 Chief Executive Officer 64 20-06-15
H. Parker BRD
 Director/Board Member 68 22-12-15
Dennis P. Wolf BRD
 Director/Board Member 71 07-11-30
Byron L. Dorgan CHM
 Chairman 81 11-02-16
Alison Moore BRD
 Director/Board Member 57 20-06-15
Jennifer Aaker BRD
 Director/Board Member 57 20-08-04
Esther Martinborough BRD
 Director/Board Member 58 21-02-01

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 70,557,577 68,294,602 ( 96.79 %) 0 96.79 %

Shareholders

NameEquities%Valuation
BlackRock Advisors LLC
9.489 %
6,671,007 9.489 % 23 M $
Nantahala Capital Management LLC
6.533 %
4,592,903 6.533 % 16 M $
Fidelity Management & Research Co. LLC
6.211 %
4,366,482 6.211 % 15 M $
Vanguard Fiduciary Trust Co.
5.872 %
4,128,428 5.872 % 14 M $
Baillie Gifford & Co.
4.863 %
3,419,093 4.863 % 12 M $
Opaleye Management, Inc.
4.332 %
3,045,525 4.332 % 11 M $
Telemark Asset Management LLC
3.835 %
2,696,411 3.835 % 9 M $
Teachers Advisors LLC
2.906 %
2,043,073 2.906 % 7 M $
Casdin Capital LLC
2.845 %
2,000,000 2.845 % 7 M $
Geode Capital Management LLC
2.154 %
1,514,392 2.154 % 5 M $

Company contact information

Codexis, Inc.

200 Penobscot Drive

94063-4718, Redwood City

+

http://www.codexis.com
address Codexis, Inc.(CDXS)

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Other Biotechnology & Medical Research

Sales per Business

Sales per region

Ratings for Codexis, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
2.66 USD
Average target price
6.571 USD
Spread / Average Target
+147.05%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
CODEXIS, INC. Stock Codexis, Inc.
-12.79% 188M
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
+1.51% 42.75B
LONZA GROUP AG Stock Lonza Group AG
+49.22% 41.61B
MODERNA, INC. Stock Moderna, Inc.
+8.57% 41.34B
CELLTRION, INC. Stock Celltrion, Inc.
-12.36% 26.59B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+8.92% 25.49B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-25.13% 18.12B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+29.17% 12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-3.12% 11.76B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+6.35% 11B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. CDXS Stock
  4. Company Codexis, Inc.